Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Chief Medical Officer | February 01, 2022 | February 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spero Therapeutics, Inc.
Report date February 01, 2022 · Filed February 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,081 |
Reported balance
After 2022-02-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-02-01 · Grant · Acquired 38,014 · Balance 62,081 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date. F2: Consists of 62,081 RSUs held by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.18 · Expires 2032-02-01 | Direct | 53,190 |
Reported balance
After 2022-02-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-01 · Grant · Acquired 53,190 · Balance 53,190 F3: The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date.
F2: Consists of 62,081 RSUs held by the Reporting Person.
F3: The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2022 Filed Feb 3, 2022 21:19 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 53,190 | $0.00 Strike: $11.18 | $0.00 |
DisclosureSEC source: 0000899243-22-004594 · doc4.xml · derivative · entry 2 Melnick David A. · CIK 0001726485 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,190 Underlying: Common Stock · 53,190 shares Expires 2032-02-01 F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:19 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 38,014 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-004594 · doc4.xml · nonDerivative · entry 1 Melnick David A. · CIK 0001726485 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,081 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date. F2 · balance_after: Consists of 62,081 RSUs held by the Reporting Person. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 20:15 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 24,067 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034503 · doc4.xml · nonDerivative · entry 1 Melnick David A. · CIK 0001726485 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,067 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 57,432 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0000899243-21-004782 · doc4.xml · derivative · entry 1 Melnick David A. · CIK 0001726485 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,432 Underlying: Common Stock · 57,432 shares Expires 2031-02-01 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 1, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 03, 2020 Filed Feb 3, 2020 22:33 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $9.34 | $0.00 |
DisclosureSEC source: 0000899243-20-002618 · doc4.xml · derivative · entry 1 Melnick David A. · CIK 0001726485 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-02-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 00:20 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0000899243-19-000181 · doc4.xml · derivative · entry 1 Melnick David A. · CIK 0001726485 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 15:11 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0000899243-18-000561 · doc4.xml · derivative · entry 1 Melnick David A. · CIK 0001726485 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on January 4, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.